Explore Brainstorm Cell Therapeutics' Q1 2025 earnings call highlights, including FDA clearance for their ALS Phase 3b trial, funding efforts, ...

BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the ...

Chaim Lebovits; President, Chief Executive Officer; Brainstorm Cell Therapeutics Inc. Hartoun Hartounian; Chief Operating Officer, Executive Vice President; Brainstorm Cell Therapeutics Inc. Ibrahim ...

Investor call and webcast scheduled for today at 8:30 a.m. ET NEW YORK, May 19, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading ...

BrainStorm Cell Therapeutics saw rising retail chatter Monday when it obtained FDA clearance for Phase 3b clinical trials of ...

FDA clearance and strategic partnerships position Brainstorm Cell Therapeutics Inc (BCLI) for a significant milestone in ALS research, despite financial hurdles.

The ACT government signals it's looking at zoning changes to enable construction of more "missing middle" housing — such as townhouses, duplexes, terrace houses, and small apartment buildings.

Every drug, vaccine and diagnostic test we take has to undergo rigorous clinical testing for safety, quality and effectiveness before it can be approved by the U.S. Food and Drug Administration (FDA) ...

Using the gene scissors CRISPR and stem cells, researchers at Stockholm University and the UK Dementia Research Institute (UK DRI) at King's College London have managed to identify a common ...

In a story of resilience and hope, the Weber family stands as a reminder of the impact of familial bonds in the face of ...

In today’s health headlines, we’re recognizing ALS Awareness Month, shedding light on the disease that affects neurons in the brain and spinal cord. Dr. Huned ...

Patients given Neuronata-R who progressed more slowly saw significant gains in CAFS, slower declines in ALSFRS-R scores, and ...